Approved indications: Ticagrelor, used by mouth, is approved to: (1) reduce the risk of cardiovascular death, heart attack, and stroke in adults with acute coronary syndrome (ACS) or a history of myocardial infarction, including reducing stent thrombosis; (2) reduce the risk of a first heart attack or stroke in adults with coronary artery disease at high risk for such events (for example many had type 2 diabetes); and (3) reduce the risk of stroke in adults with a mild acute ischemic stroke (NIHSS ≤5) or high‑risk transient ischemic attack.

Off‑label uses and evidence level: Clinicians may occasionally use ticagrelor off‑label in other high‑thrombotic‑risk settings (such as some patients with peripheral artery disease or when other P2Y12 inhibitors are unsuitable), but trial data outside the approved indications are limited or have not consistently shown clear benefit over alternatives, so these uses are individualized and based on extrapolation rather than strong guideline support.

Efficacy expectations: In ACS or prior heart attack, benefit starts within days, with fewer early heart attacks and stent clots, and persists over years as modest absolute reductions in cardiovascular death, heart attack, and stroke compared with aspirin alone or clopidogrel. In high‑risk stable coronary artery disease, ticagrelor plus low‑dose aspirin lowers the chance of a first heart attack or stroke, with small but clinically meaningful absolute risk reductions that must be weighed against more bleeding. In mild stroke or high‑risk TIA, short‑term ticagrelor plus aspirin (typically up to 30 days) reduces recurrent ischemic stroke versus aspirin alone but increases major bleeding, so it is generally used for a limited period. Overall, ticagrelor provides stronger and more rapid platelet inhibition than clopidogrel and may improve ischemic outcomes in appropriate patients, at the cost of higher rates of non‑procedural bleeding and dyspnea.

Typical dosing and how to take it:

• For acute coronary syndrome or a history of heart attack, treatment usually starts with a one‑time 180 mg loading dose (two 90 mg tablets) by mouth, followed by 90 mg twice daily; after the first year, many patients continue with 60 mg twice daily if ongoing therapy is indicated.
• For high‑risk coronary artery disease without prior heart attack or stroke, a common regimen is 60 mg twice daily.
• For mild acute ischemic stroke or high‑risk TIA, treatment typically starts with a 180 mg loading dose, then 90 mg twice daily for up to 30 days.
• Ticagrelor is usually taken together with daily low‑dose aspirin 75–100 mg, unless your clinician changes this (for example, switching to ticagrelor alone after some time following stent placement).
• Tablets can be taken with or without food, roughly 12 hours apart (for example, morning and evening) at the same times each day; swallow whole or, if you cannot swallow tablets, your provider may instruct you to crush them, mix with water, and drink immediately.

Special dosing instructions:

• Do not change the dose, stop the medication, or switch to another blood thinner without medical advice, as stopping suddenly can increase the risk of heart attack or stroke.
• If you are scheduled for surgery, dental work, or an invasive procedure, your prescriber will usually advise stopping ticagrelor about 5 days beforehand if it is safe to do so, to lower bleeding risk.
• Tell all healthcare providers, including dentists and emergency staff, that you are taking ticagrelor and aspirin.

Missed-dose guidance and overdose:

• If you miss a dose, take your next scheduled dose at the usual time and do not double up to make up for the missed tablet.
• In suspected overdose, the main risk is severe or prolonged bleeding; there is no specific antidote, and ticagrelor is not effectively removed by dialysis, so urgent medical evaluation is required—call emergency services or a poison control center right away.

Common side effects (likelihood, onset, severity):

• Bleeding and bruising (nosebleeds, gum bleeding, easy bruising, longer bleeding from cuts) are the most common effects and can occur at any time; most episodes are mild to moderate but can occasionally be serious.
• Shortness of breath (dyspnea), often described as sudden awareness of breathing or air hunger, is relatively common; it usually starts early in treatment, is often mild and transient, and is not due to lung damage, but any new or worsening breathlessness should be reported.
• Other possible effects include headache, dizziness, nausea, diarrhea, rash, and feeling tired; these are usually mild.

Serious or rare adverse effects requiring immediate medical attention:

• Signs of serious bleeding such as coughing or vomiting blood, red or black tarry stools, blood in urine, severe or uncontrollable bleeding, or unusual, large, or rapidly spreading bruises.
• Symptoms of stroke or severe brain bleed (sudden weakness, trouble speaking, vision changes, severe headache, confusion, loss of coordination).
• Allergic or hypersensitivity reactions (swelling of face, lips, tongue, or throat; trouble breathing; severe rash or hives).
• Very rare but serious blood disorders such as thrombotic thrombocytopenic purpura (TTP), which may present with fever, confusion, severe fatigue, pinpoint red spots on the skin, and dark urine.
• Slow or irregular heartbeat, fainting, or pauses in breathing, especially in people with existing conduction problems or those on other heart‑rate‑lowering drugs.

Warnings and precautions (pregnancy, breastfeeding, age, kidney/liver disease):

• Pregnancy: Human data are limited; ticagrelor is generally used in pregnancy only when the expected benefit clearly outweighs potential risks, and treatment decisions should be individualized with a cardiologist and obstetric provider.
• Breastfeeding: Ticagrelor passes into animal milk, and breastfeeding is not recommended while taking it; an alternative drug or feeding plan is usually advised.
• Children: Safety and effectiveness have not been established in pediatric patients, so ticagrelor is not routinely used in children.
• Older adults: No routine dose change is required, but older patients have a higher baseline bleeding risk and should be monitored closely.
• Kidney disease: No dose adjustment is usually needed, but kidney function and anemia should be monitored, particularly in advanced chronic kidney disease.
• Liver disease: Severe hepatic impairment is a contraindication; use with caution and close monitoring in moderate liver disease, and tell your prescriber about any history of liver problems.

Overall safety compared with similar drugs: Compared with clopidogrel, ticagrelor generally provides stronger protection from ischemic events but is associated with more non‑procedure‑related bleeding and more dyspnea, while rates of fatal bleeding are similar; unlike prasugrel, it can be used in a broader range of ACS patients, including some with prior stroke or lower body weight, but still carries a boxed warning for bleeding.

Reporting side effects and safety updates: Patients should promptly report any side effects to their healthcare provider or pharmacist, who can adjust therapy if needed. Suspected adverse reactions can also be reported directly to the FDA MedWatch program (by phone at 1‑800‑FDA‑1088 or online), and current safety communications, boxed warnings, and recall information for ticagrelor can be found on the FDA’s drug safety web pages.

Drug, supplement, food, and alcohol interactions:

• Avoid strong CYP3A inhibitors (such as ketoconazole, clarithromycin, itraconazole, ritonavir) and strong CYP3A inducers (such as rifampin, carbamazepine, phenytoin, St. John’s wort), as they can markedly raise or lower ticagrelor levels and alter its effect.
• High doses of simvastatin or lovastatin (more than 40 mg daily) can have increased blood levels when combined with ticagrelor, raising the risk of statin side effects; your clinician may choose a different statin or lower dose.
• Ticagrelor can increase blood levels of digoxin, so levels may need monitoring and dose adjustment.
• Other medicines that increase bleeding risk—such as warfarin, DOACs (apixaban, rivaroxaban, etc.), heparins, most NSAIDs (ibuprofen, naproxen), and many SSRIs/SNRIs (like sertraline, fluoxetine, venlafaxine)—can add to ticagrelor‑related bleeding risk; combined use requires careful monitoring.
• Opioid pain medicines can slow stomach emptying and reduce or delay absorption of ticagrelor; in some hospital settings a non‑oral antiplatelet may be considered.
• Daily aspirin doses above 100 mg may reduce ticagrelor’s effectiveness, so stay within the low‑dose range recommended by your prescriber and avoid duplicate aspirin‑containing products.
• Large amounts of grapefruit or grapefruit juice may increase ticagrelor levels and bleeding risk; many clinicians recommend avoiding or limiting grapefruit while on this medication.
• Alcohol does not directly interact with ticagrelor but can increase the risk of stomach irritation and bleeding, especially if you drink heavily; moderation or avoidance is usually advised.

Conditions and co‑medications that make use unsafe or require caution:

• Do not use ticagrelor if you have active pathological bleeding, a history of intracranial hemorrhage, or severe liver impairment, or if you have had a serious allergic reaction to ticagrelor before.
• Use with extra caution if you have a history of recent major bleeding, peptic ulcer disease, uncontrolled high blood pressure, recent major surgery or trauma, moderate liver disease, asthma or COPD (because of dyspnea), or a tendency to low heart rate or heart block, especially if you take other drugs that slow the heart.
• Always review all prescription and over‑the‑counter medicines, vitamins, and herbal supplements with your healthcare team before starting ticagrelor.

Monitoring needs:

• Regular clinical checks for signs of bleeding (bruising, nosebleeds, blood in stool or urine) and symptoms such as shortness of breath or dizziness.
• Periodic blood tests may be done to check hemoglobin/hematocrit, kidney function, and sometimes liver tests and uric acid, particularly in high‑risk patients.
• Heart rhythm may be monitored in people with known conduction disease or unexplained fainting or pauses.
• Ticagrelor can interfere with some platelet function tests used for diagnosing heparin‑induced thrombocytopenia (HIT), so laboratory staff and clinicians should be informed if such testing is ordered.

Q: What is ticagrelor used for?
A: Ticagrelor is a prescription antiplatelet (blood thinner) taken by mouth to lower the risk of heart attack, stroke, cardiovascular death, and stent clotting in certain adults with acute coronary syndrome, prior heart attack, high‑risk coronary artery disease, or mild ischemic stroke or high‑risk TIA.

Q: How long will I need to take ticagrelor?
A: Many people with a recent heart attack or stent take ticagrelor for at least 12 months, and some continue longer or at a lower dose based on ongoing risk and bleeding history, so the total duration should be decided with your cardiologist.

Q: Can I stop ticagrelor or skip doses before surgery or dental work?
A: Never stop ticagrelor or change how you take it on your own; for planned surgery or procedures, your prescriber will usually have you stop the drug about 5 days in advance if it is safe to do so, and restart it afterward when bleeding risk is acceptable.

Q: What should I do if I miss a dose?
A: If you miss a dose, just take your next dose at the regular time, do not double the next dose, and let your healthcare provider know if you are missing doses frequently.

Q: Is ticagrelor the same as aspirin or warfarin?
A: No; ticagrelor is an antiplatelet drug that keeps platelets from clumping, aspirin is a different type of antiplatelet, and warfarin and other anticoagulants work on clotting proteins in the blood, but all are “blood thinners” that increase bleeding risk and must be coordinated carefully.

Q: Why do I feel short of breath on ticagrelor?
A: Mild, sudden shortness of breath is a known side effect of ticagrelor and often improves over time, but because breathlessness can also signal heart or lung problems, you should always report it so your clinician can check for other causes and decide whether to continue the drug.

Storage: Store ticagrelor tablets at room temperature (about 68–77°F / 20–25°C), with short excursions allowed between 59–86°F (15–30°C); keep tablets in the original, tightly closed container, away from moisture, heat, and direct light, and out of sight and reach of children and pets.

Disposal: When tablets are no longer needed or are expired, use a local medicine take‑back program if available; if none is available, mix tablets (do not crush for this) with an unappealing substance such as used coffee grounds or cat litter, seal in a bag or container, and place in household trash, and remove or scratch out personal information on empty bottles before discarding.